Literature DB >> 16490890

Corticosteroid use in the intensive care unit: at what cost?

Rebecca C Britt1, Alicia Devine, Karen C Swallen, Leonard J Weireter, Jay N Collins, Frederic J Cole, L D Britt.   

Abstract

HYPOTHESIS: Corticosteroid use has a significant effect on morbidity and mortality in the intensive care unit (ICU).
DESIGN: Case-control study.
SETTING: Burn-trauma ICU in a level 1 trauma center. PATIENTS: All patients who received corticosteroids while in the ICU from January 1, 2002, to December 31, 2003 (n = 100), matched by age and Injury Severity Score with a control group (n = 100).
INTERVENTIONS: None. MAIN OUTCOME MEASURES: We considered the following 7 outcomes: pneumonia, bloodstream infection, urinary tract infection, other infections, ICU length of stay (LOS), ventilator LOS, and mortality.
RESULTS: Cases and controls had similar APACHE II (Acute Physiology and Chronic Health Evaluation II) scores and medical history. In univariate analysis, the corticosteroid group had a significant increase in pneumonia (26% vs 12%; P<.01), bloodstream infection (19% vs 7%; P<.01), and urinary tract infection (17% vs 8%; P<.05). In multivariate models, corticosteroid use was associated with an increased rate of pneumonia (odds ratio [OR], 2.64; 95% confidence interval [CI], 1.21-5.75) and bloodstream infection (OR, 3.25; 95% CI, 1.26-8.37). There was a trend toward increased urinary tract infection (OR, 2.31; 95% CI, 0.94-5.69), other infections (OR, 2.57; 95% CI, 0.87-7.67), and mortality (OR, 1.89; 95% CI, 0.81-4.40). Patients in the ICU who received corticosteroids had a longer ICU LOS by 7 days (P<.01) and longer ventilator LOS by 5 days (P<.01).
CONCLUSIONS: Corticosteroid use is associated with increased rate of infection, increased ICU and ventilator LOS, and a trend toward increased mortality. Caution must be taken to carefully consider the indications, risks, and benefits of corticosteroids when deciding on their use.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16490890     DOI: 10.1001/archsurg.141.2.145

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  8 in total

1.  Steroid-Induced Sleep Disturbance and Delirium: A Focused Review for Critically Ill Patients.

Authors:  Jennifer L Cole
Journal:  Fed Pract       Date:  2020-06

Review 2.  The hypothalamic-pituitary-adrenal axis in critical illness.

Authors:  Shekhar Venkataraman; Ricardo Munoz; Cristina Candido; Selma Feldman Witchel
Journal:  Rev Endocr Metab Disord       Date:  2007-12       Impact factor: 6.514

Review 3.  The effect of diabetes on mortality in critically ill patients: a systematic review and meta-analysis.

Authors:  Sarah E Siegelaar; Maartje Hickmann; Joost B L Hoekstra; Frits Holleman; J Hans DeVries
Journal:  Crit Care       Date:  2011-09-13       Impact factor: 9.097

Review 4.  Chronic Pain and Chronic Opioid Use After Intensive Care Discharge - Is It Time to Change Practice?

Authors:  Dusica M Stamenkovic; Helen Laycock; Menelaos Karanikolas; Nebojsa Gojko Ladjevic; Vojislava Neskovic; Carsten Bantel
Journal:  Front Pharmacol       Date:  2019-02-22       Impact factor: 5.810

5.  Glucocorticoid Use Audits.

Authors:  Jubbin Jagan Jacob; Sanjay Kalra
Journal:  Indian J Endocrinol Metab       Date:  2022-08-04

Review 6.  Pharmacotherapy in Coronavirus Disease 2019 and Risk of Secondary Infections: A Single-Center Case Series and Narrative Review.

Authors:  Michael Behal; Brooke Barlow; Breanne Mefford; Melissa L Thompson Bastin; J Chris Donaldson; Melanie Laine; Brittany D Bissell
Journal:  Crit Care Explor       Date:  2021-07-13

Review 7.  Intensive Care Unit-Acquired Weakness: Not just Another Muscle Atrophying Condition.

Authors:  Heta Lad; Tyler M Saumur; Margaret S Herridge; Claudia C Dos Santos; Sunita Mathur; Jane Batt; Penney M Gilbert
Journal:  Int J Mol Sci       Date:  2020-10-22       Impact factor: 5.923

8.  Cardiolipin-mediated PPARγ S112 phosphorylation impairs IL-10 production and inflammation resolution during bacterial pneumonia.

Authors:  Mayank Garg; Saumya Johri; Shakti Sagar; Aniruddha Mundhada; Anurag Agrawal; Prabir Ray; Krishnendu Chakraborty
Journal:  Cell Rep       Date:  2021-02-09       Impact factor: 9.423

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.